Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies (Tables)

v3.26.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2026
Summary of Significant Accounting Policies  
Schedule of significant expense categories

​

​

​

​

​

​

​

​

Three Months Ended

​

March 31, 

​

March 31, 

​

2026

  ​ ​ ​

2025

Operating expenses:

​

​

​

​

​

Clinical

$

1,809,420

​

$

1,817,232

Chemical, manufacturing and controls

​

265,725

​

​

135,122

Research and preclinical

​

(5,634)

​

​

24,134

Regulatory

​

14,662

​

​

21,658

Other research and development costs

​

585,606

​

​

438,852

Total research and development

​

2,669,779

​

​

2,436,998

General and administrative expenses

​

2,406,587

​

​

1,992,928

Total operating expenses

$

5,076,366

​

$

4,429,926

Sublease income

​

(19,455)

​

​

—

Loss on debt conversion with related party

​

—

​

​

6,134,120

Interest (income)/expense, net

​

(77,350)

​

​

147,090

Exchange loss, net

 

5,860

​

 

23,274

Net loss before income taxes

$

4,985,421

​

$

10,734,410